The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | Challenges of biomarker testing in the UK
Keith Kerr, BSc, MB, ChB, University of Aberdeen, Aberdeen, UK, outlines the challenges associated with the advances in biomarker testing, particularly for the UK. The increased number of biomarkers informing treatment decisions necessitates the more resourceful use of tumor samples, the implementation of blood testing to pick up on tumor-derived nucleotides, or ideally, both these methods in combination. In doing this, resource and monetary challenges follow. Further, there is the challenge of the overwhelming molecular data, which is differentiating patients into increasingly smaller subgroups, reaching the point of determining a unique tumor profile for each individual, which can be challenging to interpret which treatment options are best for patients. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
None
